Lords Mark Q1FY26 results: AGM set for Sep 30

What the board approved on August 13, 2026

Lords Mark Industries Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1FY26). The decisions were taken at a board meeting held on August 13, 2026. Alongside the financial results, the board reviewed the company’s operational performance, strategic growth roadmap, and its financial outlook for FY27. The company is formerly known as Lords Mark India Limited and Kratos Energy & Infrastructure Limited.

The meeting also recorded a key compliance development: the resignation of the company’s Company Secretary. The disclosure did not include the outgoing executive’s name or the effective date in the provided text. Still, such changes are typically tracked closely by investors because the Company Secretary is central to regulatory filings and board processes.

46th AGM date and governance agenda

The board scheduled the company’s 46th Annual General Meeting (AGM) for September 30, 2026. In addition to routine AGM business, the board recommended the appointment of new auditors for shareholder approval. The recommendations covered statutory, secretarial, internal, and cost auditors.

While the article does not specify the names of the proposed audit firms, the breadth of appointments indicates a comprehensive refresh across key assurance and compliance functions. In Indian listed-company governance, these roles support financial reporting discipline, internal control checks, and statutory compliance reporting.

Q1FY26 results: what is disclosed and what is not

The company confirmed that Q1FY26 results were approved and that the numbers are unaudited for the quarter ended June 30, 2026. However, the provided material does not include revenue, profit, margin, or segment-level figures for the quarter. As a result, any performance assessment must be limited to the fact of approval and the board’s review of operations and FY27 outlook.

For market participants, the key takeaway is the formal board sign-off and the accompanying corporate actions such as AGM scheduling and auditor recommendations, which often appear in the same regulatory communication.

Medical Devices Rules milestone: Biomescan SaMD manufacturing licence

Separately, Lords Mark Industries stated it has received a manufacturing licence for its Biomescan Analytics Platform under the Medical Devices Rules, 2017. The company described this as a first in India for an In Vitro Diagnostic Software classified as Software as a Medical Device (SaMD). It also positioned the platform as relevant to preventive healthcare and early health risk assessment.

The company referred to this as a milestone for India’s preventive healthcare ecosystem. The licensing point matters because regulated manufacturing status under the Medical Devices Rules, 2017 is a key gate for scaling medical-device and diagnostics offerings in the Indian market.

Context: gut health market growth cited by the company

The disclosure also provided market sizing for India’s gut health segment to frame the preventive health opportunity. The gut health market was valued at USD 565.51 million in 2025 and is projected to reach USD 1,619.56 million by 2034. The implied expansion is at a CAGR of 11.07%.

These numbers offer context for why diagnostic and analytics-led preventive healthcare products are drawing attention. They also indicate why a manufacturing licence for an IVD SaMD product is being highlighted alongside corporate and financial updates.

Manufacturing expansion at Vasai and planned third facility

Lords Mark Industries commissioned a new 14,000 sq. ft. In Vitro Diagnostics (IVD) manufacturing facility at Vasai (East), Maharashtra, two months ahead of its August 2026 schedule. The company stated this facility complements an existing 20,000 sq. ft. manufacturing unit, taking the total operational manufacturing space to 34,000 sq. ft.

The company said the expanded capacity will produce 56 ELISA test kits and new rapid diagnostic test kits. It also outlined a longer-term plan for a third facility in Vasai, expected to become operational from January 2029, focused on research for early detection of cancer and dedicated to Dr. A.P.J. Abdul Kalam. Beyond that, it expressed a vision to establish an AI-enabled medical device manufacturing plant in India focused on AI-enabled and imaging-based diagnostic devices.

Key facts table

Timeline of recent milestones cited

Broader corporate background included in the disclosure

The material describes Lords Mark Industries as a diversified conglomerate across three verticals: IVD and MedTech, Renewable Energy and Smart LED, and Paper. It notes the company was founded in 1998 in Mumbai by Dr. Sachidanand Upadhyay and lists its headquarters as Thane, Maharashtra. By FY24, IVD and Energy/LED each contributed approximately 41% of revenue, according to the provided text.

The company also highlighted its BSE listing timeline, stating it listed on July 9, 2026 and held an Opening Bell Ceremony at BSE’s Heritage Hall on July 10, 2026. The text describes this as the first Indian listing via the IBC PPIRP framework, involving a merger into Kratos Energy & Infrastructure Limited, described as a dormant BSE-listed entity that initiated a pre-packaged insolvency resolution process in February 2024. The disclosure also cited a market capitalisation of approximately ₹2,688 crore at listing.

Market impact and why investors may track the next steps

From a market perspective, the August 13 board decisions put three themes in focus: quarterly compliance (approval of unaudited Q1FY26 results), governance (Company Secretary resignation and a broad slate of auditor appointments), and execution (medical-device licensing and manufacturing scale-up). The SaMD manufacturing licence under Medical Devices Rules, 2017 stands out as a regulatory milestone that can influence how quickly the company can commercialise and scale a software-led IVD offering.

The upcoming AGM on September 30, 2026 becomes the key calendar event because shareholders are expected to vote on the recommended statutory, secretarial, internal, and cost auditors. Investors will also watch for subsequent disclosures that provide the detailed Q1FY26 financial numbers and any clarifications around senior compliance roles following the Company Secretary’s resignation.

Conclusion

Lords Mark Industries’ August 13, 2026 board meeting combined routine quarterly approvals with governance changes and a regulatory milestone in preventive healthcare. The company has scheduled its 46th AGM for September 30, 2026, where auditor appointments are expected to be placed for shareholder approval. Separately, the manufacturing licence for the Biomescan Analytics Platform under the Medical Devices Rules, 2017 and the commissioning of added IVD capacity at Vasai highlight the company’s stated push in diagnostics and MedTech. The next confirmed milestone on the calendar is the September AGM, with further operational and financial updates likely to follow through statutory filings.